2-amino-5-phosphonovalerate and Epilepsies, Myoclonic
2-amino-5-phosphonovalerate has been researched along with Epilepsies, Myoclonic in 1 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
Epilepsies, Myoclonic: A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Meldrum, B | 1 |
| Wardley-Smit, B | 1 |
| Halsey, M | 1 |
| Rostain, JC | 1 |
Other Studies
1 other study available for 2-amino-5-phosphonovalerate and Epilepsies, Myoclonic
| Article | Year |
|---|---|
2-Amino-phosphonoheptanoic acid protects against the high pressure neurological syndrome.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Atmospheric Pressure; Epilepsies, Myoclonic; Male | 1983 |